Your browser is no longer supported. Please, upgrade your browser.
SPPI [NASD]
Spectrum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.13 Insider Own0.20% Shs Outstand159.26M Perf Week-37.82%
Market Cap109.47M Forward P/E- EPS next Y-0.66 Insider Trans-3.69% Shs Float140.59M Perf Month-52.78%
Income-168.60M PEG- EPS next Q-0.21 Inst Own58.20% Short Float9.08% Perf Quarter-65.11%
Sales- P/S- EPS this Y-12.50% Inst Trans-11.15% Short Ratio2.57 Perf Half Y-80.50%
Book/sh0.50 P/B1.26 EPS next Y22.40% ROA-90.80% Target Price6.20 Perf Year-82.51%
Cash/sh0.77 P/C0.82 EPS next 5Y- ROE-142.70% 52W Range0.85 - 4.54 Perf YTD-50.55%
Dividend- P/FCF- EPS past 5Y-11.20% ROI- 52W High-86.17% Beta1.88
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low-26.30% ATR0.12
Employees176 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)22.34 Volatility17.75% 11.74%
OptionableYes Debt/Eq0.00 EPS Q/Q43.70% Profit Margin- Rel Volume3.08 Prev Close0.95
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume4.96M Price0.63
Recom2.20 SMA20-46.10% SMA50-55.82% SMA200-75.01% Volume15,262,672 Change-33.62%
Sep-17-20Initiated JMP Securities Mkt Outperform $12
Dec-26-19Downgrade Guggenheim Buy → Neutral
Dec-26-19Downgrade Cantor Fitzgerald Overweight → Neutral $17 → $4
Nov-27-19Resumed B. Riley FBR Buy $18
Jul-11-19Initiated B. Riley FBR Buy $18
Mar-15-19Resumed Jefferies Buy $21
Nov-12-18Reiterated B. Riley FBR Buy $35 → $29
Dec-18-17Initiated B. Riley FBR, Inc. Buy $26
Oct-24-17Initiated Guggenheim Buy $32
Oct-19-17Reiterated H.C. Wainwright Buy $20 → $29
Oct-04-17Reiterated H.C. Wainwright Buy $14 → $20
Aug-16-17Resumed H.C. Wainwright Buy $14
Feb-10-17Resumed Jefferies Buy
Nov-05-15Reiterated RBC Capital Mkts Outperform $13 → $12
Aug-07-15Reiterated RBC Capital Mkts Outperform $12 → $13
Apr-02-15Initiated FBR Capital Outperform $9
Feb-23-15Downgrade ROTH Capital Buy → Neutral $15 → $7
Jul-15-14Upgrade R. F. Lafferty Sell → Neutral $7.50
Oct-07-13Initiated HC Wainwright Buy $15
May-29-13Initiated Burrill Institutional Research Mkt Outperform $12
Jan-26-22 06:44PM  
Jan-20-22 07:00AM  
Jan-05-22 08:00AM  
Jan-04-22 07:00AM  
Dec-22-21 11:00AM  
Dec-15-21 08:07AM  
Dec-10-21 08:35AM  
Dec-06-21 10:00AM  
07:00AM  
Dec-01-21 04:00PM  
Nov-30-21 07:00AM  
Nov-11-21 07:00AM  
Nov-10-21 08:30PM  
04:00PM  
Nov-03-21 07:00AM  
06:02AM  
Nov-01-21 04:14PM  
02:36PM  
02:11PM  
01:47PM  
12:15PM  
11:30AM  
11:06AM  
10:00AM  
09:13AM  
09:11AM  
07:45AM  
Oct-31-21 10:35AM  
Oct-30-21 01:18PM  
Oct-29-21 03:53PM  
02:23PM  
02:00PM  
01:45PM  
12:40PM  
11:00AM  
09:00AM  
07:40AM  
Oct-28-21 05:45PM  
04:15PM  
03:06PM  
01:37PM  
12:30PM  
11:00AM  
08:59AM  
07:30AM  
05:19AM  
Oct-27-21 10:55PM  
10:42PM  
09:00PM  
05:38PM  
04:10PM  
02:49PM  
01:18PM  
12:31PM  
09:00AM  
07:45AM  
05:40AM  
Oct-26-21 09:45PM  
05:24PM  
03:45PM  
03:00PM  
02:00PM  
01:13PM  
12:45PM  
12:15PM  
11:29AM  
10:00AM  
09:08AM  
07:40AM  
05:40AM  
Oct-25-21 11:38PM  
03:55PM  
03:30PM  
02:50PM  
11:45AM  
11:00AM  
09:00AM  
08:07AM  
Oct-24-21 10:20AM  
Oct-23-21 01:14PM  
09:15AM  
Oct-22-21 03:35PM  
02:50PM  
11:40AM  
11:30AM  
11:00AM  
09:00AM  
08:00AM  
Oct-21-21 03:20PM  
02:48PM  
11:45AM  
11:00AM  
09:53AM  
08:25AM  
Oct-20-21 08:43PM  
07:11PM  
05:01PM  
03:30PM  
03:09PM  
02:35PM  
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEBEL FRANCOISChief Medical OfficerNov 09Sale2.186,00013,080329,166Nov 10 08:32 PM
LEBEL FRANCOISChief Medical OfficerNov 08Sale2.207,36316,221335,166Nov 10 08:32 PM
LEBEL FRANCOISChief Medical OfficerJun 23Sale4.005,00020,000340,046Jun 23 05:11 PM
LEBEL FRANCOISChief Medical OfficerJun 22Sale4.095,82123,785345,046Jun 23 05:11 PM
McGahan Keith MChief Legal OfficerJun 22Sale4.164,50018,720303,699Jun 22 06:20 PM
McGahan Keith MChief Legal OfficerJun 21Sale4.273,73515,934308,199Jun 22 06:20 PM
Fischer Seth H. Z.DirectorJun 18Sale4.2412,00050,88034,777Jun 22 05:18 PM
Vyas DolatraiDirectorJun 18Sale4.249,00038,16086,346Jun 22 05:06 PM
Ashton WilliamDirectorJun 18Sale4.249,00038,16046,943Jun 22 04:51 PM
Riga Thomas JEVP, COO & CCOMay 14Sale3.072,2506,908406,879May 14 07:31 PM
McGahan Keith MChief Legal OfficerMay 14Sale3.075251,612311,934May 14 07:27 PM
Riga Thomas JEVP, COO & CCOMay 13Sale3.093,40210,499409,129May 14 07:31 PM
McGahan Keith MChief Legal OfficerMay 13Sale3.094341,339312,459May 14 07:27 PM
LEBEL FRANCOISChief Medical OfficerApr 06Sale3.241,0253,321350,867Apr 06 05:50 PM
LEBEL FRANCOISChief Medical OfficerApr 05Sale3.311,1253,726351,892Apr 06 05:50 PM
Turgeon Joseph W.CEO & PresidentMar 16Sale3.6928,243104,217565,028Mar 17 06:53 PM
Riga Thomas JEVP, COO & CCOMar 16Sale3.6918,82869,475412,531Mar 17 06:52 PM
McGahan Keith MChief Legal OfficerMar 16Sale3.6916,31860,213316,832Mar 17 06:51 PM
LEBEL FRANCOISChief Medical OfficerMar 16Sale3.6918,82869,475353,017Mar 17 06:08 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerMar 16Sale3.6916,31860,213400,451Mar 17 06:08 PM
Turgeon Joseph W.CEO & PresidentMar 15Sale3.6240,091145,330593,271Mar 17 06:53 PM
Riga Thomas JEVP, COO & CCOMar 15Sale3.6223,29184,430431,359Mar 17 06:52 PM
McGahan Keith MChief Legal OfficerMar 15Sale3.6214,36252,062333,150Mar 17 06:51 PM
LEBEL FRANCOISChief Medical OfficerMar 15Sale3.6222,63182,037371,845Mar 17 06:08 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerMar 15Sale3.6220,36573,823416,769Mar 17 06:08 PM
McGahan Keith MChief Legal OfficerFeb 22Sale3.734,00014,920347,512Feb 23 04:33 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerFeb 22Sale3.734,00014,920437,134Feb 23 04:27 PM
Riga Thomas JEVP, COO & CCOFeb 22Sale3.735,00018,650454,650Feb 23 04:19 PM
Turgeon Joseph W.CEO & PresidentFeb 22Sale3.737,50027,975633,362Feb 23 05:00 PM
McGahan Keith MChief Legal OfficerFeb 19Sale3.643,29511,984351,512Feb 23 04:33 PM
GUSTAFSON KURT AEVP & Chief Financial OfficerFeb 19Sale3.644,67216,992441,134Feb 23 04:27 PM
Riga Thomas JEVP, COO & CCOFeb 19Sale3.645,01818,250459,650Feb 23 04:19 PM
Turgeon Joseph W.CEO & PresidentFeb 19Sale3.647,25726,394640,862Feb 23 05:00 PM
McGahan Keith MChief Legal OfficerFeb 10Sale3.932,5009,825244,498Feb 10 05:29 PM
McGahan Keith MChief Legal OfficerFeb 09Sale3.931,9777,770246,998Feb 10 05:29 PM